Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2006-11-28
2006-11-28
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C558S166000, C558S169000, C558S170000, C558S172000, C558S174000
Reexamination Certificate
active
07141557
ABSTRACT:
A method of treating viral infections, and in particular HIV-1, hepatitis B virus, and herpes virus, is disclosed. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative.
REFERENCES:
patent: 2086585 (1937-07-01), Taub et al.
patent: 2087132 (1937-07-01), Taub et al.
patent: 2108765 (1938-02-01), Domagk
patent: 2209383 (1940-07-01), Bock
patent: 2439969 (1948-04-01), Fourneau
patent: 2445393 (1948-07-01), Fourneau
patent: 2513747 (1950-07-01), Sallman et al.
patent: 2606909 (1952-08-01), Blicke
patent: 2689790 (1954-09-01), Mowry et al.
patent: 2950253 (1960-08-01), Kling et al.
patent: 3054678 (1962-09-01), Michener et al.
patent: 3694473 (1972-09-01), Eibl et al.
patent: 4093714 (1978-06-01), Tolman et al.
patent: 4096278 (1978-06-01), Queuille
patent: 4119714 (1978-10-01), Kny et al.
patent: 4159988 (1979-07-01), Eibl et al.
patent: 4221732 (1980-09-01), Oette et al.
patent: 4235877 (1980-11-01), Fullerton
patent: 4291024 (1981-09-01), Turcotte
patent: 4329302 (1982-05-01), Hanahan et al.
patent: 4426525 (1984-01-01), Hozumi et al.
patent: 4444766 (1984-04-01), Bosies et al.
patent: 4471113 (1984-09-01), MacCoss
patent: 4540521 (1985-09-01), Garst et al.
patent: 4559157 (1985-12-01), Smith et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4619917 (1986-10-01), Lee et al.
patent: 4622392 (1986-11-01), Hong et al.
patent: 4661509 (1987-04-01), Gordon et al.
patent: 4724232 (1988-02-01), Rideout et al.
patent: 4797479 (1989-01-01), Shuto et al.
patent: 4816450 (1989-03-01), Bell et al.
patent: 4820508 (1989-04-01), Wortzman
patent: 4826823 (1989-05-01), Cook et al.
patent: 4835263 (1989-05-01), Nguyen et al.
patent: 4837023 (1989-06-01), Eibl
patent: 4841039 (1989-06-01), Chu et al.
patent: 4880782 (1989-11-01), Eckstein et al.
patent: 4921951 (1990-05-01), Shuto et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 4997761 (1991-03-01), Jett-Tilton
patent: 5026687 (1991-06-01), Yarchoan et al.
patent: 5034394 (1991-07-01), Daluge
patent: 5138045 (1992-08-01), Cook et al.
patent: 5221696 (1993-06-01), Ke et al.
patent: 5496546 (1996-03-01), Wang et al.
patent: 5512671 (1996-04-01), Piantadosi et al.
patent: 5614548 (1997-03-01), Piantadosi et al.
patent: 5633388 (1997-05-01), Diana et al.
patent: 5770584 (1998-06-01), Kucera et al.
patent: 5830905 (1998-11-01), Diana et al.
patent: 5846964 (1998-12-01), Ozeki
patent: 5891874 (1999-04-01), Colacino et al.
patent: 5922757 (1999-07-01), Chojkier
patent: 5962437 (1999-10-01), Kucera et al.
patent: 5985854 (1999-11-01), Kozak
patent: 6030960 (2000-02-01), Morris-Natschke et al.
patent: 6034134 (2000-03-01), Gold et al.
patent: 6077837 (2000-06-01), Kozak
patent: 6136796 (2000-10-01), Kozak
patent: 6166089 (2000-12-01), Kozak
patent: 6670341 (2003-12-01), Kucera et al.
patent: 2004/0082242 (2004-04-01), Bottger et al.
patent: 37 26 945 (1989-02-01), None
patent: 39 34 820 (1991-04-01), None
patent: 40 10 228 (1991-10-01), None
patent: 199 14 474 (1999-10-01), None
patent: 0 094 586 (1983-11-01), None
patent: 0 109 255 (1984-05-01), None
patent: 0 142 333 (1985-05-01), None
patent: 0 145 303 (1985-06-01), None
patent: 0 146 258 (1985-06-01), None
patent: 0 252 310 (1988-01-01), None
patent: 0 310 109 (1989-04-01), None
patent: 0 335 396 (1989-04-01), None
patent: 0 348 859 (1990-01-01), None
patent: 0 350 287 (1990-01-01), None
patent: 0 416 401 (1991-03-01), None
patent: 0 434 450 (1991-06-01), None
patent: 0 506 704 (1991-07-01), None
patent: 0 632 048 (1995-01-01), None
patent: 1561630 (1969-03-01), None
patent: 2 239 243 (1991-06-01), None
patent: 42-13841 (1967-08-01), None
patent: 49-100224 (1974-09-01), None
patent: 61-238793 (1986-10-01), None
patent: 10293129 (1989-01-01), None
patent: 08-268890 (1996-10-01), None
patent: 10-101591 (1998-04-01), None
patent: 90/00555 (1990-01-01), None
patent: 90/05736 (1990-05-01), None
patent: 90/15601 (1990-12-01), None
patent: 91/05558 (1991-05-01), None
patent: 91/09602 (1991-07-01), None
patent: 91/18914 (1991-12-01), None
patent: 91/19726 (1991-12-01), None
patent: 92/03462 (1992-03-01), None
patent: 92/06192 (1992-04-01), None
patent: 93/00910 (1993-01-01), None
patent: 93/08807 (1993-05-01), None
patent: 93/16091 (1993-08-01), None
patent: 93/16092 (1993-08-01), None
patent: 93/17020 (1993-09-01), None
patent: 93/21191 (1993-10-01), None
patent: 94/28908 (1994-12-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 01/19320 (2001-03-01), None
Aggarwal, S. K. et al., “Synthesis and Biological Evaluation of Prodrugs of Zidovudine”,J. Med. Chem., 33, 1505-10 (1990).
Alt M. et al., “Core Specific Antisense Phosphorothioate Oligodeoxynucleotides as Potent and Specific Inhibitors of Hepatitis C Viral Translation”,Archives of Virology142:589-599, 1997.
Alt M. et al., “Specific Inhibition of Hepatitis C Viral GeneExpression by Antisense Phosphorothioate Oligodeoxynucleotides”,Hepatology22:707-717, Sep. 1995.
Amari et al., “Isolation of Experimental Anti-AIDS Glycerophospholipids by Micro-Preparative Reversed-Phase High-Performance Liquid Chromatography,”Journal of Chromatography, 590 (1992), 153-161.
Anderson, L. J. et al., “Antigenic Characterization of Respiratory Syncytial Virus Strains with Monoclonal Antibodies”,Journal of Infectious Diseases, 151:626-633 (Apr. 1985).
Attwood, M. R. et al., “The Design and Synthesis of Potent Inhibitors of Hepatitis C Virus NS3-4A Proteinase”,Antiviral Chemistry and Chemotherapy10:259-273, Sep. 1999.
Bartlett, “Antiretroviral Therapy in Patients with HIV Infection”, 1996,Infectious Diseases in Clinical Practice5:172-179.
Battaglia, A.M. et al., “Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection”,The Annals of Pharmacotherapy34:487-494, Apr. 2000.
Berdel et al., “Cytotoxicity of Thioether Lysophospholipids in Leukemias and tumors of Human Origin,”Cancer Research, vol. 43 (1983), 5538-5543.
Berenguer, M. et al., “Hepatitis C Virus in the Transplant Setting”,Antiviral Therapy3(Suppl. 3):125-136, 1998.
Boldanova, N. B. et al., “Protective Effect of Phosphatidylcholine-Containing Liposomes in Experimental Toxic Hepatitis”,Vopr. Med. Khim, 32, No. 3 (1986) Chemical Abstracts 105, p. 67, Abstract No. 35587k (1986).
Bosies, E. et al., “Preparation of Lecithin Analogs as Retrovirucides and Virucides”, Chemical Abstracts,115CA; 72142p 1991.
Braekman et al., “Pharmacokinetics (PK) of Depocyt™ after Intrathecal Administration for the Treatment of Leptomeningeal Metastases (LM)”, 1997,Proc. Amer. Soc. for Clinical Oncology, Abstract #810.
Capizzi, “Curative Chemotherapy for Acute Myeloid Leukemia: the Development of High-Dose Ara-C from the Laboratory to Bedside”, 1996,Investigational New Drugs14:249-256.
Chu M. et al., “Isolation and Structure of SCH 351633: A Novel Hepatitis C Virus (HCV) NS3 Protease Inhibitor from the FungusPenicillium griseofulvum”,Bioorganic and Medicinal Chemistry Letters9:1949-1952, 1999.
Chu M. et al., “Structure of Sch 68631: A New Hepatitis C Virus Proteinase Inhibitor fromStreptomycessp.”,Tetrahedron Letters37:7229-7232, 1996.
Coe et al., “Preparation of Nucleotide Mimics with Potent Inhibitory Activity Against HIV Reserve Transcriptase,”J. Chem. Soc. PerkinTrans 1 (1991), 3378-3379.
Cooper, K. E., “The Effectiveness of Ribavirin in the Treatment of RSV”,Pediatric Nursing, Jan.-Feb. 2001, 27:95-98.
Crumpton, S. et al., “Novel Lipid Analogs with Cytostatic and Cytocidal Activity”,Anticancer Research, vol. 8, No. 6, pp. 1361-1366 (Nov.-Dec. 1988).
Daniel, L. W. et al., “Alkyl-Linked Diglygerides Inhibit Protein Kinase C Activation by Diacylglycerols”,Biochemical&Biophysical Re
Ishaq Khalid S.
Kucera Louis S.
Morris-Natschke Susan L.
Coleman Brenda
Morgan & Lewis & Bockius, LLP
University of North Carolina at Chapel Hill
Wake Forest University
LandOfFree
Lipid analogs for treating viral infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipid analogs for treating viral infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipid analogs for treating viral infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3693733